ReviewNeurology international2021
Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review.
Review in Neurology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 220 papers, 15 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
220 citing papers in PubMed, 15 syntheses or guidelines pooled it.
- Effectiveness and safety of hyperbaric oxygen therapy for psychiatric disorders: A systematic review and meta-analysis.Psychiatry and clinical neurosciences · 2026Pooled it
- Efficacy of Transcranial Alternating Current Stimulation for Major Depressive Disorder and the Role of Intensity: A Systematic Review and Exploratory Meta-Analysis.Alpha psychiatry · 2026Pooled it
- Inhibition of the serotonin transporter and risk of heart valve disease: A systematic review and meta-analysis.European journal of pharmacology · 2026Pooled it
- Characterization of the Safety Profile of the Triple Monoamine Reuptake Inhibitor Dasotraline Based on Clinical Trial Data and Disproportionality Analyses of Four Related Pharmacological Classes Using Real-World Data from the FDA Adverse Event Reporting System.Clinical drug investigation · 2026Pooled it
- Short-term psychodynamic psychotherapy for social anxiety disorder: a meta-analysis of randomized controlled trials.BMC psychology · 2026Pooled it
- The effects of fluoxetine on body weight, waist circumference, and body mass index in individuals who are overweight or have obesity: a meta-analysis of randomized controlled trials.International journal of obesity (2005) · 2025Pooled it
- Exploring the efficacy of intranasal oxytocin (OXT) for anxiety and stress-related disorders through functional magnetic resonance imaging (fMRI) study: a systematic review.BMC pharmacology & toxicology · 2025Pooled it
- Efficacy of racemic ketamine or esketamine monotherapy for reducing suicidal ideation in uni- or bipolar depression: a systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2025Pooled it
- Selective Serotonin Reuptake Inhibitors (SSRIs): Effects on male fertility.JBRA assisted reproduction · 2025Pooled it
- The epidemiology and phenomenology of non-antipsychotic-induced dystonia: a hybrid systematic-narrative review.European psychiatry : the journal of the Association of European Psychiatrists · 2025Pooled it
- The Association Between Selective Serotonin Reuptake Inhibitors and the Incidence of Delirium in Critically Ill Patients: A Systematic Review.Critical care explorations · 2025Pooled it
- Comparing the effect of fluoxetine, escitalopram, and sertraline, on the level of BDNF and depression in preclinical and clinical studies: a systematic review.European journal of clinical pharmacology · 2024Pooled it
- Pooled it
- Phytochemicals in the treatment of patients with depression: a systemic review.Frontiers in psychiatry · 2024Pooled it
- Antidepressant Use and Lung Cancer Risk and Survival: A Meta-analysis of Observational Studies.Cancer research communications · 2023Pooled it
- Effect of Paroxetine or Escitalopram Coadministered with Oxycodone versus Oxycodone Alone on Ventilation during Hypercapnia: A Randomized Clinical Trial.Anesthesiology · 2026Trial
- The effect of Sudoku puzzle solving on memory and anxiety of hemodialysis patients: a randomized controlled clinical trial.International urology and nephrology · 2026Trial
- Efficacy and Safety of Escitalopram in Alleviating Depression and Anxiety Symptoms in COPD Patients: A Randomized Double-Blind Placebo-Controlled Trial.International journal of chronic obstructive pulmonary disease · 2026Trial
- The efficacy of adjunctiveThe British journal of psychiatry : the journal of mental science · 2025Trial
- The effectiveness of behavioral activation and antidepressant medication on the reduction of suicidality in patients with major depressive disorder.BMC psychiatry · 2025Trial
160 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression is the most prevalent psychiatric disorder in the world, affecting 4.4% of the global population. Despite an array of treatment modalities, depressive disorders remain difficult to manage due to many factors. Beginning with the introduction of fluoxetine to the United States in 1988, selective serotonin reuptake inhibitors (SSRIs) quickly became a mainstay of treatment for a variety of psychiatric disorders. The primary mechanism of action of SSRIs is to inhibit presynaptic reuptake of serotonin at the serotonin transporter, subsequently increasing serotonin at the postsynaptic membrane in the serotonergic synapse. The six major SSRIs that are marketed in the USA today, fluoxetine, citalopram, escitalopram, paroxetine, sertraline, and fluvoxamine, are a group of structurally unrelated molecules that share a similar mechanism of action. While their primary mechanism of action is similar, each SSRI has unique pharmacokinetics, pharmacodynamics, and side effect profile. One of the more controversial adverse effects of SSRIs is the black box warning for increased risk of suicidality in children and young adults aged 18-24. There is a lack of understanding of the complexities and interactions between SSRIs in the developing brain of a young person with depression. Adults, who do not have certain risk factors, which could be confounding factors, do not seem to carry this increased risk of suicidality. Ultimately, when prescribing SSRIs to any patient, a risk-benefit analysis must factor in the potential treatment effects, adverse effects, and dangers of the illness to be treated. The aim of this review is to educate clinicians on potential adverse effects of SSRIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.